Catalent Pharma Solutions

Catalent is a premier global provider of delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. The company is renowned for its proprietary drug delivery platforms, such as Zydis fast-dissolve and advanced softgel technologies, which enhance the bioavailability and patient compliance of diverse therapeutics. Catalent operates a vast global network of facilities, providing end-to-end services from early-phase development and clinical supply to large-scale commercial manufacturing. In late 2024, the company was acquired by Novo Holdings in a landmark $16.5 billion transaction to bolster the manufacturing capacity for GLP-1 therapies and other complex biologics. Today, it remains a critical partner for pharmaceutical and biotech companies worldwide, supporting thousands of clinical and commercial programs.